Enjoy complimentary customisation on priority with our Enterprise License!
Pulmonary hypertension is an example of a rare disease that affects arteries carrying blood to the lungs. The narrowing, or blockage of these arteries results in pulmonary hypertension. The recent increase in the sales of ERAs that gained global acceptance due to its oral mode of administration is expected to aid this market in surpassing USD 4 billion by 2019.
Technavio’s market research analyst has estimated the Americas to account for more than 52% of the total market share by 2019. This region’s high market share can be attributed to factors such as the increasing focus on combination therapies and the recent increase in the number of geriatric population in this region during the forecast period.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Pipeline portfolio
Key Information of the few pipeline candidates
PART 07: Market segmentation by type of formulation
Oral
Injection
Inhalation
PART 08: Market segmentation by mechanism of action
Endothelin receptor antagonist
Prostacyclin analogues
Phosphodiesterase inhibitors
Soluble guanylate cyclase stimulators
PART 09: Geographical segmentation
PART 10: Market drivers
Increase in incidence of pulmonary hypertension
Patient assistance programs
Newer disease modifying therapies
Unmet medical needs
PART 11: Impact of drivers
PART 12: Market challenges
Patent expiry
Poor patient compliance
Intense competition among vendors
PART 13: Impact of drivers and challenges
PART 14: Market trends
Increased focus on combination therapies
Increase in awareness of hypertension
Strategic alliances
PART 15: Vendor landscape
Competitive scenario
Key news
Mergers and acquisitions
Market share analysis 2014
Other prominent vendors
PART 16: Key vendor analysis
Actelion Pharmaceuticals
United Therapeutics
GSK
Bayer Healthcare
PART 17: Appendix
List of abbreviation
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.